ClinicalTrials.gg
Status unknownNCT05213767Updated Jan 28, 2022

Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB2916 Injection in Patients With Advanced Malignant Tumors

A Phase 1 interventional study of TQB2916 injection in Advanced Tumors, sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-01-28.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2022), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
190
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This project is an open, dose escalation and expansion phase I clinical study. The first phase is a dose escalation study, and the second phase is a dose expansion study based on the Maximum tolerated dose (MTD) / Recommended Phase II Dose (RP2D) obtained in the first phase. The purpose is to evaluate the safety, tolerability, and pharmacokinetic characteristics of TQB2916 injection in patients with advanced tumors, and to initially evaluate the antitumor efficacy of TQB2916 injection.

02

Conditions studied

  • Advanced Tumors
03

In context

Lead sponsor

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. is the lead sponsor of 53 studies on the registry; 29 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1 Subjects with advanced malignant tumors clearly diagnosed by pathology and / or cytology, lack of conventional effective treatment methods, failure or relapse after treatment.
  • 2 18-75 years old; (ECOG) physical status: 0-1; at least 3 months expected survival period.
  • 3 The function of main organs is normal.
  • 4 Subjects must need to adopt effective methods of .
  • 5 Subjects voluntarily joined the study, signed form, and with good compliance.

Exclusion criteria

Exclusion Criteria:

  • 1 Patients has had or is currently having other malignant tumors within 3 years. The following two conditions can be included in the group: other malignant tumors treated with a single operation to achieved R0 resection without recurrence and . Cured cervical carcinoma in situ, non-melanoma skin cancer, nasopharyngeal carcinoma and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor infiltrating basement membrane)].
  • 2 The toxicity of previous antitumor treatment is not recovered to ≤ grade 1 ( (CTCAE) 5.0).
  • 3 Received major surgical treatment, open or obvious traumatic injury within 28 days before treatment.
  • 4 Subjects had an arteriovenous thrombosis event within 6 months.
  • 5 Subjects occurred Evans syndrome within 3 months.
  • 6 History of drug abuse, alcohol or drug abuse or mental disorder.
  • 7 Subjects who suffered from Active tuberculosis within 1 year.
  • 8 The subjects had any history of bleeding or coagulopathy.
  • 9 Cirrhosis, active hepatitis.
  • 10 The subjects was diagnosed with renal failure and required hemodialysis or peritoneal dialysis.
  • 11 History of immunodeficiency, including positive (HIV) test or other acquired, congenital immunodeficiency disease, or history of organ transplantation.
  • 12 Subjects who have epilepsy and require treatment.
  • 13 Received the treatment of proprietary Chinese medicines with anti-tumor indications clearly stated in the National Medical Products Administration (NMPA) approved drug instructions within 2 weeks of starting treatment.
  • 14 The symptoms of subjects with known central nervous system metastasis, spinal cord compression, meningeal metastasis, or .
  • 15 Vaccination history of before 28 days of starting treatment, or planned vaccination of live attenuated vaccine during the study period.
  • 16 History of severe allergy to macromolecule drugs or known components of TQB2916 injection.
  • 17 Receiving any other agent within 4 weeks before first dose.
  • 18 According to the investigator's judgment, there are concomitant diseases that seriously endanger the safety of the subject or affect the completion of the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
190 participants (estimated)

Study arms

  • Experimental
    TQB2916 injection

    2.5mg/ quaque die (QD) was used as the initial dose, 21 days as a treatment cycle. The drug is administered on the first day of each cycle until the disease progresses or the investigator judges that it is not suitable for subject to continue to take medicine.

    Drug: TQB2916 injection

Interventions

  • TQB2916 injection is a kind of Tumor necrosis factor receptor superfamily member 5 (CD40) agonist, which is a humanized immunoglobulinG2 (IgG2) monoclonal antibody targeting CD40. This product can bind to CD40 on target cells to activate downstream signaling pathways and generate anti-tumor immune responses. At the same time, it can promote the apoptosis of B-cell lymphoma Ramos cells.

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose (MTD)

    To evaluate MTD of TQB2916 injection in patients with advanced solid tumors

    Time frame: Baseline up to 52 weeks

  2. Dose limited toxicity (DLT)

    To evaluate DLT of TQB2916 injection in Chinese adult patients with advanced solid tumors

    Time frame: Baseline up to 52 weeks

  3. Recommended Phase II Dose (RP2D)

    To evaluate RP2D of TQB2916 injection in Chinese adult patients with advanced solid tumors

    Time frame: Baseline up to 52 weeks

Secondary outcomes

  1. Adverse events (AE) , serious adverse events (SAE) and treatment-related adverse events (TRAE)

    The occurrence of all adverse events (AE), serious adverse events (SAE) and treatment-related adverse events (TRAE)

    Time frame: Baseline up to 104 weeks

  2. Tmax

    Time to reach maximum (peak) plasma concentration following drug administration

    Time frame: (-1 to 0 hour) (pre-dose), 0,1, 2, 4, 8, 24, 48,72,144,312,480 hours after intravenous injection of Cycle 1/3 Day 1; In 1 hour before intravenous injection on Cycle 2 Day 1, Cycle 4 Day 1, Cycle 5 Day 1, Cycle 6 Day 1, Cycle 7 Day 1 and Cycle 8 Day 1.

  3. Maximum (peak) plasma drug concentration (Cmax)

    Cmax is the maximum plasma concentration of TQB2916.

    Time frame: (-1 to 0 hour) (pre-dose), 0, 1, 2, 4, 8, 24, 48,72,144,312,480 hours after intravenous injection of Cycle 1/3 Day 1; In 1 hour before intravenous injection on Cycle 2 Day 1, Cycle 4 Day 1, Cycle 5 Day 1, Cycle 6 Day 1, Cycle 7 Day 1 and Cycle 8 Day 1.

  4. Elimination half-life (t1/2)

    t1/2 is time it takes for the blood concentration of TQB2916 or metabolite(s) to drop by half.

    Time frame: (-1 to 0 hour) (pre-dose), 0, 1, 2, 4, 8, 24, 48,72,144,312,480 hours after intravenous injection of Cycle 1/3 Day 1; In 1 hour before intravenous injection on Cycle 2 Day 1, Cycle 4 Day 1, Cycle 5 Day 1, Cycle 6 Day 1, Cycle 7 Day 1 and Cycle 8 Day 1.

  5. Area under the plasma concentration-time curve from time zero to time t (AUC0-t)

    To characterize the pharmacokinetics of TQB2916 by assessment of area under the plasma concentration time curve from the first dose to infinity.

    Time frame: (-1 to 0 hour) (pre-dose), 0, 1, 2, 4, 8, 24, 48,72,144,312,480 hours after intravenous injection of Cycle 1/3 Day 1; In 1 hour before intravenous injection on Cycle 2 Day 1, Cycle 4 Day 1, Cycle 5 Day 1, Cycle 6 Day 1, Cycle 7 Day 1 and Cycle 8 Day 1.

  6. Maximum (peak) steady-state plasma drug concentration during a dosage interval (Cmax,ss)

    Cmax is the maximum plasma concentration of TQB2916

    Time frame: (-1 to 0 hour) (pre-dose), 0, 1, 2, 4, 8, 24, 48,72,144,312,480 hours after intravenous injection of Cycle 1/3 Day 1; In 1 hour before intravenous injection on Cycle 2 Day 1, Cycle 4 Day 1, Cycle 5 Day 1, Cycle 6 Day 1, Cycle 7 Day 1 and Cycle 8 Day 1.

  7. Concentration at the end of the dosing interval AUCtau,ss

    To characterize the pharmacokinetics of TQB2916 by assessment of area The concentration at the end of the administration interval

    Time frame: (-1 to 0 hour) (pre-dose), 0, 1, 2, 4, 8, 24, 48,72,144,312,480 hours after intravenous injection of Cycle 1/3 Day 1; In 1 hour before intravenous injection on Cycle 2 Day 1, Cycle 4 Day 1, Cycle 5 Day 1, Cycle 6 Day 1, Cycle 7 Day 1 and Cycle 8 Day 1.

  8. Minimum steady-state plasma drug concentration during a dosage interval (Css-min)

    Cmin is the minimum plasma concentration of TQB2916

    Time frame: (-1 to 0 hour) (pre-dose), 0, 1, 2, 4, 8, 24, 48,72,144,312,480 hours after intravenous injection of Cycle 1/3 Day 1; In 1 hour before intravenous injection on Cycle 2 Day 1, Cycle 4 Day 1, Cycle 5 Day 1, Cycle 6 Day 1, Cycle 7 Day 1 and Cycle 8 Day 1.

  9. Progress Free Survival (PFS)

    Time from the first dose to the first documentation of progressive disease (PD) or death from any cause, whichever occurs first

    Time frame: up to 96 weeks

  10. Disease control rate (DCR)

    Percentage of participants achieving complete response (CR) and partial response (PR) and stable disease (SD).

    Time frame: up to 96 weeks

  11. Duration of Response (DOR)

    The time when the participants first achieved complete or partial remission to disease progression.

    Time frame: up to 96 weeks

  12. Overall survival (OS)

    the time from start of study treatment to date of death due to any cause

    Time frame: up to 96 weeks

07

Study locations

1 site
  • Tianjin Cancer Hospital
    Tianjin, Tianjin 300060, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2022; primary completion for May 2023, 15 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2022
First posted
Jan 28, 2022
StartEst.
Feb 2022
Primary completionEst.
May 2023
CompletionEst.
Jul 2023
Last update
Jan 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05213767
Responsible party
Sponsor
First posted
Jan 28, 2022
Start date
Feb 2022 (estimated)
Primary completion
May 2023 (estimated)
Completion
Jul 2023 (estimated)
Last update
Jan 28, 2022

Study contacts

Yi Ba, Doctor
Contact
bayi@tjmuch.com
18622221230
Huilai Zhang, Doctor
Contact
zhlwgq@126.com
18622221228

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TQB2916

Start the discussion